MIRM - Albireo: Reasons For A Successful Transformation Into A Commercial Company
- Albireo developed Odevixibat - a product as a pipeline - as a life-saving therapy for multiple ultra-rare pediatric liver disease indications.
- Following the approval of Odevixibat in PFIC, Albireo needs to transform into a commercial company capable of generating profits.
- Albireo is in the leadership role within the market and can successfully differentiate itself from competition to achieve a high penetration in the limited market.
- Beyond Odevixibat, Albireo was able to discover new drugs with blockbuster potential for long-term shareholder value creation.
For further details see:
Albireo: Reasons For A Successful Transformation Into A Commercial Company